WeVote
Log In

Bill

Bill

A 1040

Relates to establishing the expanded pharmaceutical insurance coverage panel

2025 Regular Session Introduced by Eddie Gibbs and 1 co-sponsor

Bill A 1040 would establish a pharmaceutical coverage review panel to expand prescription drug insurance coverage in New York, potentially increasing medication access but raising concerns about costs and implementation authority.

ENACTING CLAUSE STRICKEN
0
WeVote Research Nonpartisan
Bill Summary · A 1040

Legislative bill overview

Bill A 1040 would establish an expanded pharmaceutical insurance coverage panel in New York to review and potentially broaden prescription drug coverage under insurance plans. The bill appears designed to create a mechanism for evaluating which medications should be covered by insurers, possibly to address gaps in current formularies or ensure access to specific drug categories.

Why is this important

Pharmaceutical coverage decisions directly affect patient access to medications and out-of-pocket costs. An expanded review panel could influence which drugs insurers must cover, impacting both individual patients' ability to afford prescriptions and overall healthcare spending across the state.

Potential points of contention

  • Regulatory scope: Whether the panel has authority to override insurer decisions or merely make recommendations, and how much discretion insurers retain
  • Cost implications: Mandatory coverage expansion could increase insurance premiums for all policyholders or reduce insurer profit margins
  • Panel composition: Who sits on the panel and whether representation includes patient advocates, manufacturers, insurers, and physicians—affecting whose interests are prioritized
  • Implementation status: The January 28 action striking the "enacting clause" suggests significant revisions; the bill's current viability and actual provisions are unclear

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.